Monday, March 4, 2024 Tools Underestimate Cardiovascular Event Risk in People with HIV Transmission electron micrograph of HIV-1 virus particles (blue) replicating from the plasma membrane of an H9 T cell (green). Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID A new analysis from the NIAID and NHLBI supported REPRIEVE trial presented at the 2024 Conference on Retroviruses and Opportunistic Infections found that current tools underestimated cardiovascular risk in Black people and cisgender women with HIV. Study investigators suggest that updated tools are needed to facilitate precision, high-quality care of the diverse population living with HIV. These studies also underscore the necessity for representative inclusion in clinical trials. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107